Mechelen, Belgium-based Galapagos NV has entered into a global, multi-year strategic alliance with Swiss drug major Roche to develop potential new therapies for chronic obstructive pulmonary disease (COPD), which could earn the former more than 400 million euros ($573 million).
News of the deal pushed Galapagos' shares 6.6% higher to 9.05 euros, while Roche moved up an imperceptible 0.1% to 178.70 Swiss francs, despite also announcing US approval for its rheumatoid arthritis drug Actemra (tocilizumab) ahead of the weekend (The Pharma Letter January 11).
Under the terms of the agreement, Galapagos has received a research access payment of 6 million euros from Roche, and is also eligible to get discovery, development, regulatory and sales milestone payments that could potentially exceed 400 million euros, plus royalties upon commercialization of any products covered in the agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze